Gabapentin Capsule
Product Images NDC 72162-2138

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 72162-2138). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustration showing a formula for calculating creatinine clearance (CLCr), which factors in age, weight, serum creatinine levels, and includes an adjustment for female patients by multiplying by 0.85.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of gabapentin, showing a cyclohexane ring bonded to a chain with an amino group and a carboxylic acid group.*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph showing mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks including baseline, and the y-axis shows mean pain scores from 0 to 10. The graph indicates a 4-week dose titration period followed by a 4-week fixed-dose period. Gabapentin shows a decline in mean pain score over time, while placebo remains relatively stable.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line chart illustrating mean pain scores over 7 weeks comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks from baseline through a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. Gabapentin groups show decreasing pain scores over time, with scores lower than placebo throughout the study.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing data for two studies. It compares placebo (PBO) and gabapentin (GBP) treatments at different dosages (GBP 1800, GBP 2400, GBP 3600), with response proportions ranging from 12% to 34%, noting statistical significance with p-values less than 0.01 and 0.001.*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot showing the percentage difference on the vertical axis and daily dose in milligrams on the horizontal axis. The graph compares results from three studies labeled as STUDY a, STUDY b, and STUDY c at daily doses of 600, 900, 1200, and 1800 mg. Each study's data points are represented with different shading: solid black for STUDY a, gray for STUDY b, and white for STUDY c. The graph illustrates trends in percentage differences across varying daily doses for the three studies.*

FDA Label Image

Label (Lbl721622138)

Label for Gabapentin Capsules, USP 100 mg, supplied in a package of 100 capsules. The label shows storage instructions (store at 20° to 25°C with permitted excursions), dispensing requirements including child-resistant closure, and manufacturer info: Bryant Ranch Prepack as relabeler and ACI Healthcare Limited as manufacturer. The label includes the NDC 72162-2138-1 and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.